Alvotech Holdings SA, develops and manufactures biosimilars for global markets. The company is headquartered in Iceland.
| Revenue (TTM) | $494.61M |
| Gross Profit (TTM) | $300.04M |
| EBITDA | $75.73M |
| Operating Margin | -11.10% |
| Return on Equity | 0.00% |
| Return on Assets | 2.19% |
| Revenue/Share (TTM) | $1.68 |
| Book Value | $-0.54 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | 3.28 |
| EV/Revenue | 5.96 |
| EV/EBITDA | 19.33 |
| Quarterly Earnings Growth (YoY) | -99.00% |
| Quarterly Revenue Growth (YoY) | -38.90% |
| Shares Outstanding | $356.82M |
| Float | $140.79M |
| % Insiders | 59.68% |
| % Institutions | 12.80% |
Volatility is currently contracting
Alvotech (ALVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alvotech is transitioning from supply remediation to throughput, with FDA-cleared facilities and multiple key biosimilar filings advancing toward decisions this quarter. ALVO's guidance implies a significant second-half revenue and EBITDA ramp, hinging on restored manufacturing capacity and upcoming product launches. Recent manufacturing upgrades and expanded partnerships position ALVO to compete on supply reliability and cost, crucial in crowded biosimilar markets.
REYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that members of the management team will participate in upcoming investor conferences in November as follows:
ALVO, CSIQ and AESI have been added to the Zacks Rank #5 (Strong Sell) List on October 21, 2026.
Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech's biosimilars portfolio
AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg)
Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics' Syracuse facility in New York Strategic long-term partnership to increase Alvotech's global manufacturing capacity and support growth in demand REYKJAVIK, Iceland, and SEOUL, South Korea (October 6, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and LOTTE Biologics, a contract development and manufacturing (CDMO) organization, today announced a long-term strategic manufacturing partnership. Under the agreement, LOTTE Biologics will manufacture drug substance for multiple antibody biosimilar products at its Syracuse facility in New York for global supply, with the potential to further expand the collaboration over time.
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech's two Reykjavik drug substance suites
Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) prefilled syringe and autoinjector for subcutaneous administration.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ALVO and any ticker you trade — then tracks every position and per-strategy win rate.
